Blood-brain barrier dysfunction, seizures and epilepsy

Seminars in Cell and Developmental Biology

Volumn 38, Issue , 2015, Pages 26-34

  van Vliet, E A ^a   Aronica, E ^a   Gorter, J A ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Albumin; Blood brain barrier; Epileptogenesis; Temporal lobe epilepsy; Traumatic brain injury

Indexed keywords

TIGHT JUNCTION PROTEIN;

BLOOD BRAIN BARRIER; HUMAN; MEDICAL RESEARCH; NEUROLOGIC DISEASE; PATHOGENESIS; REVIEW; ANIMAL; EPILEPSY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEIZURES;

ANIMALS; BLOOD-BRAIN BARRIER; EPILEPSY; HUMANS; SEIZURES;

EID: 84928211132     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.10.003     Document Type: Review

References (107)

1. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
2. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57:173-185.
3. Friedman A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg?. Epilepsia 2011, 52(Suppl. 8):19-20.
4. Heinemann U., Kaufer D., Friedman A. Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 2012, 60:1251-1257.
5. Marchi N., Granata T., Ghosh C., Janigro D. Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia 2012, 53:1877-1886.
6. Shlosberg D., Benifla M., Kaufer D., Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010, 6:393-403.
7. Vezzani A., French J., Bartfai T., Baram T.Z. The role of inflammation in epilepsy. Nat Rev Neurol 2011, 7:31-40.
8. Van Vliet E.A., da Costa Araújo S., Redeker S., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534.
9. Seiffert E., Dreier J.P., Ivens S., Bechmann I., Tomkins O., et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 2004, 24:7829-7836.
10. Ivens S., Kaufer D., Flores L.P., Bechmann I., Zumsteg D., et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007, 130:535-547.
11. Tomkins O., Friedman O., Ivens S., Reiffurth C., Major S., et al. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis 2007, 25:367-377.
12. Marchi N., Oby E., Batra A., Uva L., De Curtis M., et al. In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia 2007, 48:1934-1946.
13. Marchi N., Fan Q., Ghosh C., Fazio V., Bertolini F., et al. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol Dis 2009, 33:171-181.
14. Korn A., Golan H., Melamed I., Pascual-Marqui R., Friedman A. Focal cortical dysfunction and blood-brain barrier disruption in patients with postconcussion syndrome. J Clin Neurophysiol 2005, 22:1-9.
15. Tomkins O., Shelef I., Kaizerman I., Eliushin A., Afawi Z., et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry 2008, 79:774-777.
16. Tomkins O., Feintuch A., Benifla M., Cohen A., Friedman A., et al. Blood-brain barrier breakdown following traumatic brain injury: a possible role in posttraumatic epilepsy. Cardiovasc Psychiatry Neurol 2011, 2011:765923.
17. Ehrlich P. Das Sauerstoffbedürfnis des Organismus. Eine farbanalytische Studie 1885, Hirschwald-Verlag, Berlin.
18. Jasper H.H. Physiopathological mechanisms of post-traumatic epilepsy. Epilepsia 1970, 11:73-80.
19. Nitsch C., Klatzo I. Regional patterns of blood-brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J Neurol Sci 1983, 59:305-322.
20. Gurses C., Orhan N., Ahishali B., Yilmaz C.U., Kemikler G., et al. Topiramate reduces blood-brain barrier disruption and inhibits seizure activity in hyperthermia-induced seizures in rats with cortical dysplasia. Brain Res 2013, 1494:91-100.
21. Ahishali B., Kaya M., Orhan N., Arican N., Ekizoglu O., et al. Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia. Life Sci 2010, 87:609-619.
22. Sokrab T.E., Kalimo H., Johansson B.B. Endogenous serum albumin content in brain after short-lasting epileptic seizures. Brain Res 1989, 489:231-236.
23. Bolwig T.G., Hertz M.M., Westergaard E. Acute hypertension causing blood-brain barrier breakdown during epileptic seizures. Acta Neurol Scand 1977, 56:335-342.
24. Johansson B., Nilsson B. The pathophysiology of the blood-brain barrier dysfunction induced by severe hypercapnia and by epileptic brain activity. Acta Neuropathol 1977, 38:153-158.
25. Petito C.K., Schaefer J.A., Plum F. Ultrastructural characteristics of the brain and blood-brain barrier in experimental seizures. Brain Res 1977, 127:251-267.
26. Michalak Z., Sano T., Engel T., Miller-Delaney S.F., Lerner-Natoli M., et al. Spatio-temporally restricted blood-brain barrier disruption after intra-amygdala kainic acid-induced status epilepticus in mice. Epilepsy Res 2013, 103:167-179.
27. Zattoni M., Mura M.L., Deprez F., Schwendener R.A., Engelhardt B., et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 2011, 31:4037-4050.
28. Marchi N., Johnson A.J., Puvenna V., Johnson H.L., Tierney W., et al. Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures. Epilepsia 2011, 52:1627-1634.
29. Lassmann H., Petsche U., Kitz K., Baran H., Sperk G., et al. The role of brain edema in epileptic brain damage induced by systemic kainic acid injection. Neuroscience 1984, 13:691-704.
30. Ruth R.E. Increased cerebrovascular permeability to protein during systemic kainic acid seizures. Epilepsia 1984, 25:259-268.
31. Zucker D.K., Wooten G.F., Lothman E.W. Blood-brain barrier changes with kainic acid-induced limbic seizures. Exp Neurol 1983, 79:422-433.
32. Van Vliet E.A., Otte W.M., Gorter J.A., Dijkhuizen R.M., Wadman W.J. Longitudinal assessment of blood-brain barrier leakage during epileptogenesis in rats. A quantitative MRI study. Neurobiol Dis 2014, 63:74-84.
33. Leroy C., Roch C., Koning E., Namer I.J., Nehlig A. In the lithium-pilocarpine model of epilepsy, brain lesions are not linked to changes in blood-brain barrier permeability: an autoradiographic study in adult and developing rats. Exp Neurol 2003, 182:361-372.
34. Ndode-Ekane X.E., Hayward N., Grohn O., Pitkanen A. Vascular changes in epilepsy: functional consequences and association with network plasticity in pilocarpine-induced experimental epilepsy. Neuroscience 2010, 166:312-332.
35. Rigau V., Morin M., Rousset M.C., de Bock F., Lebrun A., et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007, 130:1942-1956.
36. Ravizza T., Gagliardi B., Noe F., Boer K., Aronica E., et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008, 29:142-160.
37. Pereira de Vasconcelos A., Mazarati A.M., Wasterlain C.G., Nehlig A. Self-sustaining status epilepticus after a brief electrical stimulation of the perforant path: a 2-deoxyglucose study. Brain Res 1999, 838:110-118.
38. Handforth A., Treiman D.M. Functional mapping of the late stages of status epilepticus in the lithium-pilocarpine model in rat: a 14C-2-deoxyglucose study. Neuroscience 1995, 64:1075-1089.
39. Handforth A., Treiman D.M. Functional mapping of the early stages of status epilepticus: a 14C-2-deoxyglucose study in the lithium-pilocarpine model in rat. Neuroscience 1995, 64:1057-1073.
40. VanLandingham K.E., Lothman E.W. Self-sustaining limbic status epilepticus. I. Acute and chronic cerebral metabolic studies: limbic hypermetabolism and neocortical hypometabolism. Neurology 1991, 41:1942-1949.
41. Dreier J.P. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011, 17:439-447.
42. Winkler M.K., Chassidim Y., Lublinsky S., Revankar G.S., Major S., et al. Impaired neurovascular coupling to ictal epileptic activity and spreading depolarization in a patient with subarachnoid hemorrhage: possible link to blood-brain barrier dysfunction. Epilepsia 2012, 53(Suppl. 6):22-30.
43. Stanimirovic D.B., Friedman A. Pathophysiology of the neurovascular unit: disease cause or consequence. J Cereb Blood Flow Metab 2012, 32:1207-1221.
44. Roch C., Leroy C., Nehlig A., Namer I.J. Magnetic resonance imaging in the study of the lithium-pilocarpine model of temporal lobe epilepsy in adult rats. Epilepsia 2002, 43:325-335.
45. Bouilleret V., Boyet S., Marescaux C., Nehlig A. Mapping of the progressive metabolic changes occurring during the development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy. Brain Res 2000, 852:255-262.
46. Librizzi L., Noe F., Vezzani A., de Curtis M., Ravizza T. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012, 72:82-90.
47. Boer K., Jansen F., Nellist M., Redeker S., van den Ouweland A.M., et al. Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008, 78:7-21.
48. Prabowo A.S., Iyer A.M., Anink J.J., Spliet W.G., van Rijen P.C., et al. Differential expression of major histocompatibility complex class I in developmental glioneuronal lesions. J Neuroinflammation 2013, 10:12.
49. Schmitz A.K., Grote A., Raabe A., Urbach H., Friedman A., et al. Albumin storage in neoplastic astroglial elements of gangliogliomas. Seizure 2013, 22:144-150.
50. Raabe A., Schmitz A.K., Pernhorst K., Grote A., von der Brelie C., et al. Cliniconeuropathologic correlations show astroglial albumin storage as a common factor in epileptogenic vascular lesions. Epilepsia 2012, 53:539-548.
51. Jansen L.A., Uhlmann E.J., Crino P.B., Gutmann D.H., Wong M. Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. Epilepsia 2005, 46:1871-1880.
52. Schiering I.A., de Haan T.R., Niermeijer J.M., Koelman J.H., Majoie C.B., et al. Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia. J Neuropathol Exp Neurol 2014, 73:324-334.
53. Csuka E., Morganti-Kossmann M.C., Lenzlinger P.M., Joller H., Trentz O., et al. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol 1999, 101:211-221.
54. Van Vliet E.A., Zibell G., Pekcec A., Schlichtiger J., Edelbroek P.M., et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
55. Kang E.J., Major S., Jorks D., Reiffurth C., Offenhauser N., et al. Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions. Neurobiol Dis 2013, 52:204-218.
56. Rosenberg G.A. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012, 32:1139-1151.
57. Mihaly A., Bozoky B. Immunohistochemical localization of extravasated serum albumin in the hippocampus of human subjects with partial and generalized epilepsies and epileptiform convulsions. Acta Neuropathol (Berl) 1984, 65:25-34.
58. Chassidim Y., Veksler R., Lublinsky S., Pell G.S., Friedman A., et al. Quantitative imaging assessment of blood-brain barrier permeability in humans. Fluids Barriers CNS 2013, 10:9.
59. Ravizza T., Noe F., Zardoni D., Vaghi V., Sifringer M., et al. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis 2008, 31:327-333.
60. Marchi N., Teng Q., Ghosh C., Fan Q., Nguyen M.T., et al. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 2010, 1353:176-186.
61. Liu J.Y., Thom M., Catarino C.B., Martinian L., Figarella-Branger D., et al. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012, 135:3115-3133.
62. Michalak Z., Lebrun A., Di Miceli M., Rousset M.C., Crespel A., et al. IgG leakage may contribute to neuronal dysfunction in drug-refractory epilepsies with blood-brain barrier disruption. J Neuropathol Exp Neurol 2012, 71:826-838.
63. Cornford E.M., Hyman S., Cornford M.E., Landaw E.M., Delgado-Escueta A.V. Interictal seizure resections show two configurations of endothelial Glut1 glucose transporter in the human blood-brain barrier. J Cereb Blood Flow Metab 1998, 18:26-42.
64. Frigerio F., Frasca A., Weissberg I., Parrella S., Friedman A., et al. Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia 2012, 53:1887-1897.
65. Braganza O., Bedner P., Huttmann K., von Staden E., Friedman A., et al. Albumin is taken up by hippocampal NG2 cells and astrocytes and decreases gap junction coupling. Epilepsia 2012, 53:1898-1906.
66. Bar-Klein G., Cacheaux L.P., Kamintsky L., Prager O., Weissberg I., et al. Losartan prevents acquired epilepsy via TGF-beta signaling suppression. Ann Neurol 2014, 75:864-875.
67. Cacheaux L.P., Ivens S., David Y., Lakhter A.J., Bar-Klein G., et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci 2009, 29:8927-8935.
68. David Y., Cacheaux L.P., Ivens S., Lapilover E., Heinemann U., et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis. J Neurosci 2009, 29:10588-10599.
69. Lapilover E.G., Lippmann K., Salar S., Maslarova A., Dreier J.P., et al. Peri-infarct blood-brain barrier dysfunction facilitates induction of spreading depolarization associated with epileptiform discharges. Neurobiol Dis 2012, 48:495-506.
70. Kovacs R., Heinemann U., Steinhauser C. Mechanisms underlying blood-brain barrier dysfunction in brain pathology and epileptogenesis: role of astroglia. Epilepsia 2012, 53(Suppl. 6):53-59.
71. Wallraff A., Kohling R., Heinemann U., Theis M., Willecke K., et al. The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci 2006, 26:5438-5447.
72. Hawkins R.A. The blood-brain barrier and glutamate. Am J Clin Nutr 2009, 90:867S-874S.
73. Breschi G.L., Cametti M., Mastropietro A., Librizzi L., Baselli G., et al. Different permeability of potassium salts across the blood-brain barrier follows the Hofmeister series. PLOS ONE 2013, 8:e78553.
74. Somjen G.G. Ion regulation in the brain: implications for pathophysiology. Neuroscientist 2002, 8:254-267.
75. Gurses C., Ekizoglu O., Orhan N., Ustek D., Arican N., et al. Levetiracetam decreases the seizure activity and blood-brain barrier permeability in pentylenetetrazole-kindled rats with cortical dysplasia. Brain Res 2009, 1281:71-83.
76. Tabernero A., Granda B., Medina A., Sanchez-Abarca L.I., Lavado E., et al. Albumin promotes neuronal survival by increasing the synthesis and release of glutamate. J Neurochem 2002, 81:881-891.
77. Ralay Ranaivo H., Patel F., Wainwright M.S. Albumin activates the canonical TGF receptor-smad signaling pathway but this is not required for activation of astrocytes. Exp Neurol 2010, 226:310-319.
78. Ralay Ranaivo H., Wainwright M.S. Albumin activates astrocytes and microglia through mitogen-activated protein kinase pathways. Brain Res 2010, 1313:222-231.
79. Weissberg I., Reichert A., Heinemann U., Friedman A. Blood-brain barrier dysfunction in epileptogenesis of the temporal lobe. Epilepsy Res Treat 2011, 2011:143908.
80. Vezzani A., Aronica E., Mazarati A., Pittman Q.J. Epilepsy and brain inflammation. Exp Neurol 2013, 244:11-21.
81. Kim S.Y., Buckwalter M., Soreq H., Vezzani A., Kaufer D. Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia 2012, 53(Suppl. 6):37-44.
82. Abbott N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000, 20:131-147.
83. Yu B., Shinnick-Gallagher P. Interleukin-1 beta inhibits synaptic transmission and induces membrane hyperpolarization in amygdala neurons. J Pharmacol Exp Therapy 1994, 271:590-600.
84. Fabene P.F., Navarro Mora G., Martinello M., Rossi B., Merigo F., et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med 2008, 14:1377-1383.
85. Maggio N., Cavaliere C., Papa M., Blatt I., Chapman J., et al. Thrombin regulation of synaptic transmission: implications for seizure onset. Neurobiol Dis 2013, 50:171-178.
86. Maggio N., Shavit E., Chapman J., Segal M. Thrombin induces long-term potentiation of reactivity to afferent stimulation and facilitates epileptic seizures in rat hippocampal slices: toward understanding the functional consequences of cerebrovascular insults. J Neurosci 2008, 28:732-736.
87. Willmore L.J., Rubin J.J. Antiperoxidant pretreatment and iron-induced epileptiform discharges in the rat: EEG and histopathologic studies. Neurology 1981, 31:63-69.
88. Sharma V., Babu P.P., Singh A., Singh S., Singh R. Iron-induced experimental cortical seizures: electroencephalographic mapping of seizure spread in the subcortical brain areas. Seizure 2007, 16:680-690.
89. Mohanraj R., Brodie M.J. Outcomes in newly diagnosed localization-related epilepsies. Seizure 2005, 14:318-323.
90. Vezzani A., Friedman A. Brain inflammation as a biomarker in epilepsy. Biomark Med 2011, 5:607-614.
91. Engel J., Pitkanen A., Loeb J.A., Dudek F.E., Bertram E.H., et al. Epilepsy biomarkers. Epilepsia 2013, 54(Suppl. 4):61-69.
92. Zeng L.H., Rensing N.R., Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009, 29:6964-6972.
93. Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
94. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia 2010, 51:27-36.
95. Ljungberg M.C., Bhattacharjee M.B., Lu Y., Armstrong D.L., Yoshor D., et al. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 2006, 60:420-429.
96. Van Vliet E.A., Forte G., Holtman L., den Burger J.C., Sinjewel A., et al. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 2012, 53:1254-1263.
97. Gorter J.A., Iyer A., White I., Colzi A., van Vliet E.A., et al. Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. Neurobiol Dis 2013, 62:508-520.
98. Bot A.M., Debski K.J., Lukasiuk K. Alterations in miRNA levels in the dentate gyrus in epileptic rats. PLOS ONE 2013, 8:e76051.
99. Hu K., Zhang C., Long L., Long X., Feng L., et al. Expression profile of microRNAs in rat hippocampus following lithium-pilocarpine-induced status epilepticus. Neurosci Lett 2011, 488:252-257.
100. Song Y.J., Tian X.B., Zhang S., Zhang Y.X., Li X., et al. Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain Res 2011, 1387:134-140.
101. Kan A.A., van Erp S., Derijck A.A., de Wit M., Hessel E.V., et al. Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell Mol Life Sci 2012, 69:3127-3145.
102. McKiernan R.C., Jimenez-Mateos E.M., Bray I., Engel T., Brennan G.P., et al. Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLOS ONE 2012, 7:e35921.
103. Deng X., Zhong Y., Gu L., Shen W., Guo J. MiR-21 involve in ERK-mediated upregulation of MMP9 in the rat hippocampus following cerebral ischemia. Brain Res Bull 2013, 94:56-62.
104. Iyer A., Zurolo E., Prabowo A., Fluiter K., Spliet W.G., et al. MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLOS ONE 2012, 7:e44789.
105. Aronica E., Fluiter K., Iyer A., Zurolo E., Vreijling J., et al. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci 2010, 31:1100-1107.
106. Lopez-Ramirez M.A., Wu D., Pryce G., Simpson J.E., Reijerkerk A., et al. MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J 2014, 28:2551-2565.
107. Krueger D.A., Wilfong A.A., Holland-Bouley K., Anderson A.E., Agricola K., et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74:679-687.